Delphine Claus

Publications (2)2.92 Total impact

• Article: [Patient education for osteoarthritis].

  Emmanuel Coudeyre, Delphine Claus, Jean-Michel Ristori
  [show abstract] [hide abstract]
  ABSTRACT: Therapeutic education is part of the nonpharmacological management of osteoarthritis (OA) both at the medical and surgical phase. The aim of education at an early stage of OA is to change patients' lifestyle, especially the regular practice of physical activity and weight reduction. When a surgical option is considered, the aim of education is to hasten patient recovery, improve autonomy after surgery, facilitate the return home and reduce the rate of transfer to a rehabilitation unit. Like other nonpharmacological treatment, therapeutic education implementation seems insufficient for OA management. One way to improve therapeutic education in the management of OA could be to propose dedicated continuing medical education programs supported by specific economic sources for health care professionals.
  La Presse Médicale 11/2010; 39(11):1195-200. · 0.67 Impact Factor
• Article: Effects of anti-tumor necrosis factor therapy on lipid profile in patients with rheumatoid arthritis.

  Martin Soubrier, Pierre Jouanel, Sylvain Mathieu, David Poujol, Delphine Claus, Jean Jacques Dubost, Jean Michel Ristori
  [show abstract] [hide abstract]
  ABSTRACT: Analyse the effects of anti-tumor necrosis factor therapy on serum levels of lipid in patients with rheumatoid arthritis (RA). Twenty-nine patients (26 females, 3 males) with established RA undergoing anti-TNF therapy (n=12, adalimumab; n=11, infliximab; n=6, etanercept) were recruited. Total cholesterol, LDL-cholesterol, HDL-cholesterol, triglycerides (TG), and apolipoproteins (apo b and apo a) were assessed at baseline and after 14 weeks of treatment. The disease activity index score (DAS(28)) was 5.19+/-0.90 and decreased to 3.46+/-0.97 at 16 weeks (p<0.001). There was no change neither in the levels of TC (5.65+/-0.98mmol/l vs 5.78+/-1.06mmol/l; p=0.43), TG (1.40+/-0.79mmol/l vs 1.45+/-0.67mmol/l; p=0.59), HDL-C (1.92+/-0.49mmol/l vs 1.97+/-0.49mmol/l; p=0.36), apo a1 (1.92+/-0.28g/l vs 1.99+/-0.29g/l; p=0.06), and LDL-C (3.41+/-0.91mmol/l vs 3.47+/-0.96mmol/l; p=0.66), nor in apo b (1.126+/-0.302g/l vs 1.13+/-0.28g/l; p=0.89), atherogenic index (3.13+/-1.05 vs 3.09+/-0.89; p=0.69) or the apo b/apo a1 ratio (0.58+/-0.25 vs 0.56+/-0.22; p=0.33). The favourable effect of anti-tumor necrosis factor therapy on cardiovascular morbidity is not related to effects on lipid metabolism.
  Joint, bone, spine: revue du rhumatisme 01/2008; 75(1):22-4. · 2.25 Impact Factor